このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

iBio マネジメント

マネジメント基準チェック /34

iBio'sの CEO はMartin Brennerで、 Jan2021年に任命され、の在任期間は 3.42年です。の年間総報酬は$ 1.07Mで、 42.8%給与と57.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.075%を直接所有しており、その価値は$ 16.53K 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と6.7年です。

主要情報

Martin Brenner

最高経営責任者

US$1.1m

報酬総額

CEO給与比率	42.8%
CEO在任期間	3.5yrs
CEOの所有権	0.07%
経営陣の平均在職期間	2.9yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

CEO報酬分析

iBio の収益と比較して、Martin Brenner の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	n/a	n/a	-US$21m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$1m	US$458k	-US$29m
Mar 31 2023	n/a	n/a	-US$35m
Dec 31 2022	n/a	n/a	-US$35m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	US$1m	US$405k	-US$30m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	n/a	n/a	-US$20m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	US$1m	US$178k	-US$23m

報酬と市場: Martinの総報酬 ($USD 1.07M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Martinの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Martin Brenner (53 yo)

3.5yrs

在職期間

US$1,069,174

報酬

Dr. Martin B. Brenner DVM., Ph D., is Chief Executive Officer of iBio, Inc. from June 27, 2023 and serves as its Director since June 01, 2024. Dr. Brenner was Interim CEO of iBio, Inc. from January 20, 202...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Martin Brenner	CEO, Chief Scientific Officer & Director	3.5yrs	US$1.07m	0.075% $ 12.4k
Felipe Duran	Chief Financial Officer	1.4yrs	US$1.23m	0.014% $ 2.4k
Stephen Kilmer	Investor Relations Officer	no data	データなし	データなし
Marc Banjak	General Counsel	2.3yrs	データなし	データなし
Robert Kay	Interim Secretary & Interim Treasurer	3.8yrs	US$92.69k	データなし

2.9yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: IBIOの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Martin Brenner	CEO, Chief Scientific Officer & Director	less than a year	US$1.07m	0.075% $ 12.4k
Robert Erwin	Member of Scientific Advisory Board	3.6yrs	US$291.75k	データなし
William Clark	Independent Chairman	2.9yrs	US$73.01k	0.0042% $ 695.4
Gary Sender	Lead Independent Director	3.8yrs	US$71.41k	0.0049% $ 803.0
Vidadi Yusibov	Member of Scientific Advisory Board	19.8yrs	データなし	データなし
James Hill	Independent Director	15.9yrs	US$55.00k	0.0046% $ 758.3
Timothy Blackwell	Member of Clinical Advisory Board	10yrs	データなし	データなし
Richard Silver	Member of Clinical Advisory Board	10yrs	データなし	データなし
J. Huggins	Member of Clinical Advisory Board	10yrs	データなし	データなし
Thomas Medsger	Member of Clinical Advisory Board	9.8yrs	データなし	データなし
Evert Schimmelpennink	Independent Director	3.1yrs	US$57.50k	0.0043% $ 718.6
Alexandra Kropotova	Independent Director	3.8yrs	US$52.50k	0.0049% $ 803.0

6.8yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: IBIOの取締役会は経験豊富であると考えられます ( 6.7年の平均在任期間)。

iBio マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

iBio, Inc., Annual General Meeting, Nov 27, 2023

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. Announces Executive Changes

Recent updates

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. (NYSEAM:IBIO) for $8.5 million.

New major risk - Financial position

iBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC

iBio, Inc. announced that it expects to receive $15.068742 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors

New major risk - Financial position

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $4.780385 million.

New major risk - Financial position

iBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx

iBio, Inc., Annual General Meeting, Nov 27, 2023

New minor risk - Insider selling

New major risk - Market cap size

iBio, Inc. Appoints Dr. Martin Brenner as CEO

iBio, Inc. Announces the Expansion of Its AI-Powered Technology Stack with the Launch of EngageTx

Third quarter 2023 earnings released: US$0.48 loss per share (vs US$1.42 loss in 3Q 2022)

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

First half 2023 earnings released: US$1.93 loss per share (vs US$1.97 loss in 1H 2022)

iBio, Inc. Appoints Felipe Duran as Interim Chief Financial Officer, Effective as of February 13, 2023

iBio, Inc. Announces Resignation of Robert Lutz, the Chief Financial and Business Officer as an Executive Officer, Effective February 10, 2023

High number of new and inexperienced directors

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

iBio, Inc. to Showcase the RubrYc Discovery Engine During Poster Presentations At Antibody Engineering & Therapeutics Conference 2022

iBio, Inc. Announces Executive Changes

iBio, Inc. Announces the Resignation of Thomas F. Isett as a Member of the Board

iBio, Inc. Appoints William D. (Chip) Clark as Chairman

iBio, Inc., Annual General Meeting, Dec 08, 2022

iBio, Inc. Files a Provisional Patent with the United States Patent and Trademark Office Title 'Epidermal Growth Factor Receptor Variant III Antibodies'

iBio, Inc. announced delayed annual 10-K filing

iBio, Inc. to Report Q4, 2022 Results on Sep 27, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

Consensus forecasts updated

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

iBio, Inc. to Report Q3, 2022 Results on May 12, 2022

Price target decreased to US$1.75

Consensus revenue estimates fall by 52%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

iBio, Inc. to Report Q2, 2022 Results on Feb 14, 2022

iBio, Inc. Shares an Update on Its Lead COVID-19 Vaccine Program, IBIO-202

iBio, Inc Announces Update for its Lead COVID-19 Vaccine Program, IBIO-202, in Light of the Emergence of the Omicron (B.1.1.529) Variant of SARS-CoV-2

Price target decreased to US$2.25

First quarter 2022 earnings released: US$0.041 loss per share (vs US$0.047 loss in 1Q 2021)

iBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of Fiscal 2022

Full year 2021 earnings released: US$0.12 loss per share (vs US$0.61 loss in FY 2020)

Independent Director Seymour Flug has left the company

High number of new directors

iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate

iBio, Inc.(NYSEAM:IBIO) dropped from Russell Microcap Growth Index

Third quarter 2021 earnings released: US$0.036 loss per share (vs US$0.059 loss in 3Q 2020)

iBio, Inc. Reports Successful Covid-19 Vaccine Toxicology Study Results and Announces Next-Gen Covid-19 Vaccine Program

iBio, Inc. and Fraunhofer USA, Inc. Concludes Litigation

Revenue beats expectations

Second quarter 2021 earnings released: US$0.043 loss per share (vs US$0.69 loss in 2Q 2020)

iBio, Inc. Appoints Robert M. Lutz as Chief Financial & Business Officer, Effective March 4, 2021

iBio, Inc. to Report Q2, 2021 Results on Feb 16, 2021

New 90-day high: US$2.17

iBio's (NYSEMKT:IBIO) Wonderful 324% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: US$1.08

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Price target lowered to US$2.00

iBio, Inc. Announces Resignation of Robert L. Erwin as President

iBio, Inc. has completed a Follow-on Equity Offering in the amount of $32.493644 million.

iBio to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

iBio, Inc. to Report Q1, 2021 Results on Nov 16, 2020

iBio, Inc. Appoints Randy J. Maddux as Chief Operating Officer, Effective December 1, 2020

iBio, Inc. Announces Appointment of Members to Committees

iBio, Inc. Appoints Gary Sender to Its Board of Directors

iBio, Inc. Announces the Appointment of Linda Armstrong to Board of Directors

iBio Regains Compliance with NYSE American Continued Listing Standards

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

iBio, Inc. announced delayed annual 10-K filing

マネジメント基準チェック /34